Table 3.
Comparison between pregnant women and non-pregnant female patients with HFRS.
| Pregnant | Non-pregnant | P-value | |
|---|---|---|---|
| patients | female patients | ||
| Present address | |||
| City | 6 | 25 | 0.506 |
| Country | 21 | 62 | |
| Patients with source | |||
| Shaanxi or Xi'an | 25 | 78 | 0.937 |
| Other places outside Shaanxi | 2 | 9 | |
| HFRS vaccination history | |||
| Yes | 1 | 4 | 1.000 |
| No | 26 | 83 | |
| Time from onset to admission (day) | 4.96 ± 1.65 | 4.98 ± 2.08 | 0.158 |
| Average stay | 11.15 ± 4.41 | 10.98 ± 4.81 | 0.516 |
| ICU admission | |||
| Yes | 1 | 3 | 1.000 |
| No | 26 | 84 | |
| Tmax | 39.27 ± 0.80 | 39.25 ± 0.78 | 0.429 |
| Hypotensive shock (n/%) | 8 (29.6) | 17 (19.5) | 0.268 |
| Severe complications (n/%) | 15 (55.6) | 40 (46.0) | 0.384 |
| Hemorrhage | 2 (7.4) | 6 (6.9) | 1.000 |
| Secondary infection | 9 (33.3) | 32 (46.8) | 0.744 |
| Hepatic injury | 7 (25.9) | 20 (23.0) | 0.754 |
| Sepsis | 1 (3.7) | 2 (2.3) | 0.559 |
| MODS | 4 (14.8) | 4 (4.6) | 0.166 |
| Arrhythmia | 3 (11.1) | 3 (3.4) | 0.144 |
| Pulmonary edema | 8 (29.6) | 5 (5.7) | 0.002 |
| ARDS | 1 (3.7) | 2 (2.3) | 0.559 |
| DIC | 1 (3.7) | 2 (2.3) | 0.559 |
| Encephalopathy | 0 (0) | 1 (1.1) | 1.000 |
| Multiple stages overlapping (n/%) | 10 (35.7) | 19 (21.8) | 0.113 |
| Hyperleukocytosis (n/%) | 23 (85.2) | 61 (70.1) | 0.120 |
| #Maximum leukocyte counts, ×109/L | 10.67–25.20 | 9.10–18.19 | 0.145 |
| #Nadir platelet count, ×109/L | 31–76 | 24–79 | 0.122 |
| #Platelet distribution width, fL | 16.08–17.78 | 16.0–18.2 | 0.929 |
| Thrombocytopenia (n/%) | 22 (81.5) | 70 (80.5) | 0.906 |
| Anemia at admission (n/%) | 9 (33.3) | 4 (4.6) | 0.000 |
| #Nadir hemoglobin, g/L | 79.5–89.5 | 92–109 | 0.238 |
| Hypoalbuminemia at admission (n/%) | *23 (95.83) | 73 (83.9) | 0.24 |
| Hypoalbuminemia during hospitalization (n/%) | *20 (83.33) | 53 (60.92) | 0.040 |
| #Nadir serum albumin, g/L | 21.60–29.73 | 26.90–30.20 | 0.034 |
| Renal disfunction (n/%) | 26 (96.3) | 76 (87.4) | 0.335 |
| #Maximum urea nitrogen, mmol/L | 10.53–17.54 | 7.48–23.00 | 0.066 |
| #Maximum serum creatinine, umol/L | 169–415.8 | 181.9–507.75 | 0.135 |
| CRRT treatment (n/%) | 3 (11.1) | 4 (4.6) | 0.440 |
| #Maximum procalcitonin, ug/L | 1.25–7.15 | 0.33–4.36 | 0.195 |
| #Maximum C-reactive protein, mg/L | 27.99–75.25 | 18.55–52.40 | 0.521 |
| Clinical classification of HFRS (n/%) | |||
| Mild type | 7 (25.9) | 50 (57.5) | 0.008 |
| Moderate type | 5 (18.5) | 18 (20.7) | |
| Severe type | 7 (25.9) | 7 (8.0) | |
| Gravis type | 8 (29.6) | 12 (13.8) | |
HFRS, Hemorrhagic fever with renal syndrome; ICU, intensive care unit; T, temperature; MODS, multiple organ dysfunction syndrome; ARDS, acute respiratory distress syndrome; DIC, dissinted intrvsculr cogultion; CRRT, continuous renal replacement. Date is expressed as number (%) and
#
interquartile range.
*
24 patients had albumin level during hospitalization.